SCIENCE OF CERTAINTY

Progress your preclinical
drug development
with speed and certainty

Q1‑2026 STATEMENT

Trading statement Q1‑2026

Continued advancement of Biotech portfolio

Gubra kicks off the year with solid progress across its biotech portfolio and advancing clinical programs, including key obesity assets moving towards Phase 2 and a major step toward first-in-human studies for GUB-UCN2. Alongside this, the launch of Gubra Ventures marks a new chapter in accelerating innovation and future growth.

Our CRO business continues to demonstrate resilience in a challenging market, delivering strong quarter-on-quarter growth and expanding into new therapeutic areas.

Read the full Q1 trading statement and join the investor call.

AnnouncementInvestor Webcast

R&D PIPELINE

target and peptide drug discovery

Gubra Biotech

R&D Pipeline

Pipeline

Learn More

Drug Discovery & Development

Drug Discovery & Development

Gubra has a long history of successful peptide drug discovery. Our AI-driven streaMLine platform quickly develops a peptide hit into a clinical ready drug candidate with balanced properties and strong IP protection. We do linear peptides, cyclic peptides, disulfide-rich peptides (DRP), peptide drug-conjugates and more.

Learn More

Partnering

Partnering

Gubra is known as a professional and scientific strong collaboration partner, and we have several successful partnerships ongoing. Our agile and data-driven approach to project management is valued by our partners and is key to our success and speed. Partnerships are important to us, and we always look for new collaboration opportunities.

Learn More

CRO SERVICES

Highly Specialized Preclinical Solutions

Gubra CRO

Swipe to see all services

Liver (MASH)

Liver (MASH)

Explore our industry-leading preclinical MSH model portfolio. Our GAN DIO-MASH mouse model is ranked #1 by the LITMUS consortium for human translatability. Profile your drug candidate in our biopsy-confirmed mouse models of MASH, using clinical endpoints and AI-assisted histological analyses.

Learn More

Obesity

Obesity

We have more than 15 years experience within preclinical obesity studies to help progress your drug candidate. We provide off-the-shelf diet-induced obese (DIO) rodent models for profiling the efficacy and mode of action of your compound on endpoints ranging from food intake over energy expenditure to whole-brain activation signatures.

Learn More

Kidney

Kidney (CKD/DKD)

Progress your drug discovery with Gubra’s broad portfolio of mouse models recapitulating acute and chronic kidney diseases. Our ReninAAV hypertension-accelerated diabetic kidney disease (DKD) mouse is one of the most advanced models available for profiling drug candidates with therapeutic potential in DKD.

Learn More

CNS

CNS

Gubra’s unique 3D light sheet imaging platform can visualize drug distribution, map drug targets and quantify therapeutic responses in the intact brain at single cell resolution. Our fully automated light sheet imaging pipeline accommodates up to 100 brains per study with a fast turn-around time of 2.5 months. Get instant access to your imaging data in our interactive atlas-guided 3D brain-viewer.

CNS_front
Learn More

Lung (IPF)

Lung (IPF)

We provide end-to-end customized studies in our spirometry-confirmed and bleomycin-induced mouse models of idiopathic pulmonary fibrosis (IPF). Accelerate your drug candidate by exploring pivotal lung functional endpoints in combination with AI-assisted histopathological scoring and quantitative histology.

Learn More

Diabetes

Diabetes

We are experts in preclinical diabetes research, and offer customized studies in canonical rodent models of type 2 and type 1 diabetes to guide development of your anti-diabetic compound. Study data provided by our multidisciplinary teams can inform about efficacy on metabolic and glycemic endpoints as well as whole-pancreas islet and β-cell numbers for interpreting mode of action.

Learn More

Women's Health

Women’s Health

We offer preclinical female health animal models for primary ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS). We evaluate reproductive system function through estrous cycle monitoring, oocyte counts, and follicle classification using both traditional histology and whole-ovary light-sheet fluorescence microscopy (LSFM).

Gubra. Labs 1-4 Hørsholm
Learn More

Muscle (Sarcopenia)

Muscle (Sarcopenia)

Our integrated muscle research platform enables comprehensive assessment of muscle size, composition, and function. Using AI-powered 3D imaging, we deliver high-resolution, quantitative analysis of histological endpoints within intact muscle compartments, combined with advanced in vivo and ex vivo readouts for a multidimensional view of muscle biology.

GUBRA53070
Learn More

3D imaging

3D imaging

Gubra’s light-sheet microscopy platform allows for 3D imaging of all organs in the mouse and rat. Our fully automated imaging pipeline works seamlessly in combination with our in vivo models and in-house developed AI-driven image analysis to ensure precision-mapping of drug distribution and quantification of histological endpoints.

Learn More

2D histology

Histology

High-quality histology is essential in preclinical drug development and can inform about drug mode of action. We offer routine and advanced histology services, including core histology, multiplex immunohistochemistry and RNAScope®.

Col1a1_5-6Nx_Rat
Learn More

RNAseq

RNAseq

We offer a full palette of advanced sequencing technologies, including bulk RNAseq, single-nucleus RNAseq, spatial transcriptomics and ATACseq. We accept most types of tissues, including fresh frozen or archival samples (FFPE). Trust Gubra for fast turnaround and expert bioinformatics. Get instant access to your data in GubraView, our interactive data viewer.

Learn More

Non-rodent

Non-rodent studies

Advance your preclinical drug candidate by performing PK and gut microbiome studies in minipigs, a non-rodent model of choice in late-stage preclinical drug development programs.

minipigs_forside
Learn More

VENTURES

Venture creation and incubation

Gubra Ventures

What is a venture?

Some opportunities are best advanced in Gubra Biotech, while others benefit from the focus, speed, and optionality that dedicated venture structures provide. A maturing platform meets a changing innovation landscape. Ventures is a differentiated model built on depth, discipline, and partnership.

Learn more

ABOUT US

Science with purpose

About us

Biotech, CRO & Ventures

Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future.

About us

 

Workplace full of opportunities

We offer an exciting and challenging work environment, where job satisfaction and personal development are top priorities. Together, we are scientific entrepreneurs. Explore our open positions if you would like to join the Gubra team.

Learn More

INVESTORS

We are scientific entrepreneurs

Investors

Investor Relations

We are committed to providing our shareholders and the media with reliable and transparent information about our business, discovery & development programs and results in an open and timely manner.

Learn More

Gubra announces deal with AbbVie amounting to more than $ 2.2 billion

The agreement enables AbbVie to develop GUBamy, our in-house developed, best-in-class, long-acting amylin analog in development for weight management. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales.

Press release

GUBRA GREEN

We act responsibly

Sustainability

Governance and ESG Oversight

At Gubra, human and planetary health are inseparable.
We embed ESG in everything we do and commit 10% of pre-tax profits to a net-zero, nature-positive future—beyond our own footprint.

Explore our approach below:

ESGGubra Green

CONTACT

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top